Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy.

Citation metadata

From: PeerJ(Vol. 9)
Publisher: PeerJ. Ltd.
Document Type: Clinical report
Length: 6,315 words
Lexile Measure: 1470L

Document controls

Main content

Abstract :

Background Direct Acting Antivirals (DAAs) represent a large improvement in the treatment of chronic hepatitis C, resulting in Methods A descriptive, ambispective, longitudinal study was conducted. A cohort of 261 adult patients received PegIFN[alpha]2a+RBV therapy before 2014; 167 (64%) did not respond, 83 of these were subsequently treated with SOF/LDV ±RBV or OBV/PTV/r/DSV ±RBV. Child-Pugh-Score (CPS), Fibrosis-4 (FIB-4), and AST to Platelet Ratio Index (APRI) were evaluated before and after treatment. Results SVR with PegIFN[alpha]2a+RBV was 36%, and 97.5% with DAAs. CPS, FIB-4 and APRI improved significantly after DAA treatment, mainly because of liver transaminase reduction. Conclusions DAA treatment showed excellent SVR rates in Mexican patients who had not responded to PegIFN[alpha]2a+RBV therapy. Improvement in CPS, FIB-4 and APRI without improvement in fibrosis was observed in cirrhotic and non-cirrhotic patients, as well as considerable reduction in liver transaminases, which suggests a reduction in hepatic necroinflammation.

Source Citation

Source Citation   

Gale Document Number: GALE|A675804391